Gene Therapy for Leber's Congenital Amaurosis is Safe and Effective Through 1.5 Years After Vector Administration

This publication has 27 references indexed in Scilit:

• HumanRPE65Gene Therapy for Leber Congenital Amaurosis: Persistence of Early Visual Improvements and Safety at 1 Year
  Human Gene Therapy, 2009
• Vision 1 Year after Gene Therapy for Leber's Congenital Amaurosis
  New England Journal of Medicine, 2009
• Mutations in SPATA7 Cause Leber Congenital Amaurosis and Juvenile Retinitis Pigmentosa
  American Journal of Human Genetics, 2009
• Treatment of Leber Congenital Amaurosis Due toRPE65Mutations by Ocular Subretinal Injection of Adeno-Associated Virus Gene Vector: Short-Term Results of a Phase I Trial
  Human Gene Therapy, 2008
• Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics
  Proceedings of the National Academy of Sciences, 2008
• Leber congenital amaurosis: Genes, proteins and disease mechanisms
  Progress in Retinal and Eye Research, 2008
• Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
  New England Journal of Medicine, 2008
• Effect of Gene Therapy on Visual Function in Leber's Congenital Amaurosis
  New England Journal of Medicine, 2008
• Reversal of Blindness in Animal Models of Leber Congenital Amaurosis Using Optimized AAV2-mediated Gene Transfer
  Molecular Therapy, 2008
• Eye Movement Recordings as an Effectiveness Indicator of Gene Therapy inRPE65-Deficient Canines: Implications for the Ocular Motor System
  Investigative Opthalmology & Visual Science, 2006